These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 32533524)

  • 1. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.
    Mattingly TJ; Love BL; Khokhar B
    Pharmacoeconomics; 2020 Sep; 38(9):927-939. PubMed ID: 32533524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J; He T; Lopez-Olivo MA
    Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J; He T; Hur C; Lopez-Olivo MA
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-healthcare costs of hepatitis C: a systematic review.
    Pascual-Argente N; Puig-Junoy J; Llagostera-Punzano A
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):19-30. PubMed ID: 28844170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.
    Crespo J; Cuadrado A; Perelló C; Cabezas J; Llerena S; Llorca J; Cedillo S; Llop E; Escudero MD; Hernández Conde M; Puchades L; Redondo C; Fortea JI; Gil de Miguel A; Serra MA; Lazarus JV; Calleja JL
    J Viral Hepat; 2020 Apr; 27(4):360-370. PubMed ID: 31755634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.
    He T; Lopez-Olivo MA; Hur C; Chhatwal J
    Aliment Pharmacol Ther; 2017 Oct; 46(8):711-721. PubMed ID: 28836278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
    Wei X; Zhao J; Yang L
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Mattingly TJ; Perfetto EM; Johnson SL
    Hepatology; 2018 Feb; 67(2):774-781. PubMed ID: 28834597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost burden of hepatitis C virus treatment in commercially insured patients.
    Lu CY; Ross-Degnan D; Zhang F; LeCates R; Lupton C; Sherman M; Wagner A
    Am J Manag Care; 2019 Dec; 25(12):e379-e387. PubMed ID: 31860232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
    Castro R; Perazzo H; de Araujo LAMM; Gutierres IG; Grinsztejn B; Veloso VG
    PLoS One; 2020; 15(2):e0229143. PubMed ID: 32084187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan.
    Zhuo Y; Hayashi T; Chen Q; Aggarwal R; Hutin Y; Chhatwal J
    Sci Rep; 2020 Mar; 10(1):4089. PubMed ID: 32139872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.
    Marquez LK; Chaillon A; Soe KP; Johnson DC; Zosso JM; Incerti A; Loarec A; Nguyen A; Walker JG; Mafirakureva N; Lo Re Iii V; Wynn A; McIntosh C; Kiene SM; Brodine S; Garfein RS; Vickerman P; Martin NK
    BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33627360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.